Adaptimmune Therapeutics (ADAP) News Today $0.66 -0.01 (-1.48%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial PositionNovember 19 at 2:46 PM | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Rise in Monday TradingNovember 18 at 6:42 PM | msn.comEquities Analysts Offer Predictions for ADAP FY2024 EarningsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for Adaptimmune Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. He now forecasts that the biotechnology company willNovember 18 at 2:46 AM | marketbeat.comGuggenheim Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $3.00November 18 at 1:35 AM | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Price Target Cut to $3.50 by Analysts at HC WainwrightNovember 17, 2024 | americanbankingnews.comAdaptimmune Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comAdaptimmune nears second sarcoma approval as Phase II trial hits endpointsNovember 16, 2024 | msn.comAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Rating Lowered by StockNews.comNovember 16, 2024 | americanbankingnews.comAdaptimmune price target lowered to $3 from $4 at GuggenheimNovember 15, 2024 | markets.businessinsider.comAdaptimmune Therapeutics: Strategic Realignment and Cautious Optimism for Future GrowthNovember 15, 2024 | markets.businessinsider.comGuggenheim Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock PriceGuggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday.November 15, 2024 | marketbeat.comQ1 Earnings Forecast for ADAP Issued By HC WainwrightAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst A. He anticipates that the biotechnoloNovember 15, 2024 | marketbeat.comPhiladelphia life sciences firm reducing headcount by 33%November 15, 2024 | bizjournals.comAdaptimmune price target lowered to $3.50 from $4 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comScotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)November 14, 2024 | markets.businessinsider.comAdaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy RatingNovember 14, 2024 | markets.businessinsider.comAdaptimmune trading halted, news pendingNovember 14, 2024 | markets.businessinsider.comAdaptimmune’s Strategic Shift and Financial UpdateNovember 14, 2024 | markets.businessinsider.comAdaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comBaillie Gifford & Co. Increases Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Baillie Gifford & Co. increased its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 10.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,775,860 shares of the biotNovember 13, 2024 | marketbeat.comAn Overview of Adaptimmune Therapeutics's EarningsNovember 12, 2024 | benzinga.comAdaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on WednesdayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 9, 2024 | marketbeat.comAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Scientific and Medical Conferences this November and DecemberNovember 5, 2024 | finanznachrichten.deADAP Adaptimmune Therapeutics plcOctober 18, 2024 | seekingalpha.comOTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCROctober 10, 2024 | msn.comLong Focus Capital Management LLC Has $12.04 Million Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Long Focus Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 15.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,346,September 27, 2024 | marketbeat.comAdaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutionsSeptember 25, 2024 | finance.yahoo.comAdaptimmune's T-Cell Therapy Journey: A Small Market, Big AmbitionsSeptember 12, 2024 | seekingalpha.comAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Two Bank Conferences this SeptemberAugust 29, 2024 | finanznachrichten.deBaillie Gifford & Co. Reduces Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Baillie Gifford & Co. trimmed its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 4.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,149,203 shares of the biotechnology company's sAugust 25, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Above 50-Day Moving Average of $1.10Adaptimmune Therapeutics (NASDAQ:ADAP) Share Price Passes Above 50 Day Moving Average of $1.10August 24, 2024 | marketbeat.comShort Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Grows By 13.2%Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 7,130,000 shares, a growth of 13.2% from the July 15th total of 6,300,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is currently 3.5 days.August 16, 2024 | marketbeat.comHold Rating on Adaptimmune Amid Commercialization and Financial UncertaintiesAugust 15, 2024 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years agoAugust 15, 2024 | finance.yahoo.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) to Post Q3 2024 Earnings of ($0.24) Per Share, HC Wainwright ForecastsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of Adaptimmune Therapeutics in a research note issued to investors on Tuesday, August 13th. HC Wainwright analyst A. He now anticipates that the bioteAugust 15, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Raised to Strong-Buy at StockNews.comStockNews.com raised shares of Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday.August 13, 2024 | marketbeat.comBuy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong PipelineAugust 13, 2024 | markets.businessinsider.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comHC Wainwright Reiterates "Buy" Rating for Adaptimmune Therapeutics (NASDAQ:ADAP)HC Wainwright reissued a "buy" rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a report on Tuesday.August 13, 2024 | marketbeat.comBuy Rating Justified by Adaptimmune’s Promising Financials and Strong Product Launch ProspectsAugust 12, 2024 | markets.businessinsider.comAdaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.comADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | markets.businessinsider.comBP_CCB RP1911F (66756.HK)August 12, 2024 | finance.yahoo.comAdaptimmune leads in soft tissue sarcoma therapy with first TCR approvalAugust 9, 2024 | finance.yahoo.comSeed Therapeutics enters into collaboration deal valued at up to $1.5B with Japan-based EisaiAugust 8, 2024 | bizjournals.comOutperform Rating Affirmed for Adaptimmune Following FDA Approval and Positive Market Outlook for TecelraAugust 7, 2024 | markets.businessinsider.comAdaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on MondayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing earnings before the market opens on Monday, August 12, Zacks reports.August 6, 2024 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)August 5, 2024 | markets.businessinsider.comAdaptimmune granted FDA accelerated nod for lead assetAugust 2, 2024 | msn.comFDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A DecadeAugust 2, 2024 | msn.com Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼0.430.45▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼273▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PGEN News CLLS News FATE News ATRA News BLUE News MBIO News TRDA News ABUS News DNTH News CRMD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts